Vivek K. Vishnudas, Ph.D.

In his role as Senior Vice President, Preclinical Discovery and Chief Technology Officer, Vivek Vishnudas, Ph.D., oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies. Drug-discovery programs are based on the novel disease targets identified through the use of Interrogative Biology^®. Dr. Vishnudas leads an interdisciplinary team of drug-discovery scientists, biochemists, and DMPK scientists to illuminate target biology & pharmacology while working closely with regulatory, analytics and biomarker teams.

Dr. Vishnudas manages the external R&D collaboration with industrial and academic partners and aims to scale up Berg’s R&D therapeutics portfolio. He is a co-inventor of the Interrogative Biology^® technology and continues to spearhead development activities of “data-driven” technologies that enable drug discovery programs. His breadth of operations covers scientific leadership, strategic R&D initiatives, and commercial and intellectual property strategies.

Prior to moving to industry, Dr. Vishnudas was a research fellow in the Senator Paul D. Wellstone Center for Excellence in Muscular Dystrophy/BBRI, where he completed his postdoctoral training. Through his graduate school (University of Vermont) and postdoctoral fellowship, Vivek received extensive training in the field of muscle physiology and skeletal muscle diseases. Vivek has more than 10 U.S. and international patent applications that cover wide areas of metabolic disease, oncology, and neurological indications.

Dr. Vishnudas received a Master’s degree in Biochemistry from the National Dairy Research Institute (NDRI, ICAR India) and a Ph.D. in Biology from the University of Vermont.